p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation

K. Honda, E. Sbisà, A. Tullo, P. A. Papeo, C. Saccone, S. Poole, M. Pignatelli, R. R. Mitry, S. Ding, A. Isla, A. Davies, N. A. Habib

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion between residues 156 and 157 (exon 5) and these are reported for the first time in HCC. Likewise, the silent mutation polymorphism in codon 213 was noticed in 3 of the 42 patients. Survival analysis of these patients after surgery showed the mean and median survival in patients with wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months. The difference was statistically significant (P = 0.003).

Original languageEnglish
Pages (from-to)776-782
Number of pages7
JournalBritish Journal of Cancer
Volume77
Issue number5
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Mutation
Survival
Exons
Neoplasms
Codon
Alcoholic Liver Cirrhosis
Denaturing Gradient Gel Electrophoresis
Survival Analysis
Hepatitis
Fibrosis
Genes

Keywords

  • Cirrhosis
  • Hepatitis
  • Liver carcinoma
  • Oncosuppressor gene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Honda, K., Sbisà, E., Tullo, A., Papeo, P. A., Saccone, C., Poole, S., ... Habib, N. A. (1998). p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. British Journal of Cancer, 77(5), 776-782.

p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. / Honda, K.; Sbisà, E.; Tullo, A.; Papeo, P. A.; Saccone, C.; Poole, S.; Pignatelli, M.; Mitry, R. R.; Ding, S.; Isla, A.; Davies, A.; Habib, N. A.

In: British Journal of Cancer, Vol. 77, No. 5, 1998, p. 776-782.

Research output: Contribution to journalArticle

Honda, K, Sbisà, E, Tullo, A, Papeo, PA, Saccone, C, Poole, S, Pignatelli, M, Mitry, RR, Ding, S, Isla, A, Davies, A & Habib, NA 1998, 'p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation', British Journal of Cancer, vol. 77, no. 5, pp. 776-782.
Honda, K. ; Sbisà, E. ; Tullo, A. ; Papeo, P. A. ; Saccone, C. ; Poole, S. ; Pignatelli, M. ; Mitry, R. R. ; Ding, S. ; Isla, A. ; Davies, A. ; Habib, N. A. / p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. In: British Journal of Cancer. 1998 ; Vol. 77, No. 5. pp. 776-782.
@article{6f6e69e01ead4a1786b63b29bbda7323,
title = "p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation",
abstract = "Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion between residues 156 and 157 (exon 5) and these are reported for the first time in HCC. Likewise, the silent mutation polymorphism in codon 213 was noticed in 3 of the 42 patients. Survival analysis of these patients after surgery showed the mean and median survival in patients with wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months. The difference was statistically significant (P = 0.003).",
keywords = "Cirrhosis, Hepatitis, Liver carcinoma, Oncosuppressor gene",
author = "K. Honda and E. Sbis{\`a} and A. Tullo and Papeo, {P. A.} and C. Saccone and S. Poole and M. Pignatelli and Mitry, {R. R.} and S. Ding and A. Isla and A. Davies and Habib, {N. A.}",
year = "1998",
language = "English",
volume = "77",
pages = "776--782",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation

AU - Honda, K.

AU - Sbisà, E.

AU - Tullo, A.

AU - Papeo, P. A.

AU - Saccone, C.

AU - Poole, S.

AU - Pignatelli, M.

AU - Mitry, R. R.

AU - Ding, S.

AU - Isla, A.

AU - Davies, A.

AU - Habib, N. A.

PY - 1998

Y1 - 1998

N2 - Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion between residues 156 and 157 (exon 5) and these are reported for the first time in HCC. Likewise, the silent mutation polymorphism in codon 213 was noticed in 3 of the 42 patients. Survival analysis of these patients after surgery showed the mean and median survival in patients with wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months. The difference was statistically significant (P = 0.003).

AB - Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion between residues 156 and 157 (exon 5) and these are reported for the first time in HCC. Likewise, the silent mutation polymorphism in codon 213 was noticed in 3 of the 42 patients. Survival analysis of these patients after surgery showed the mean and median survival in patients with wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months. The difference was statistically significant (P = 0.003).

KW - Cirrhosis

KW - Hepatitis

KW - Liver carcinoma

KW - Oncosuppressor gene

UR - http://www.scopus.com/inward/record.url?scp=15144343103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15144343103&partnerID=8YFLogxK

M3 - Article

C2 - 9514057

AN - SCOPUS:15144343103

VL - 77

SP - 776

EP - 782

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -